Clinical Trials Logo

Varicella clinical trials

View clinical trials related to Varicella.

Filter by:

NCT ID: NCT00985166 Completed - Measles Clinical Trials

A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)

Start date: August 2000
Phase: Phase 3
Study type: Interventional

The study was conducted to determine if ProQuad may be used in place of the second dose of M-M-R II routinely given to children 4 to 6 years old who were previously immunized with M-M-R II and Varivax.

NCT ID: NCT00985153 Completed - Measles Clinical Trials

Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)

Start date: March 2000
Phase: Phase 3
Study type: Interventional

This study will compare three consistency lots of ProQuad to each other as well as to M-M-R II and Varivax, administered concomitantly at different injection sites, with respect to immunogenicity, safety, and tolerability.

NCT ID: NCT00984295 Completed - Measles Clinical Trials

Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines

Start date: June 2000
Phase: Phase 3
Study type: Interventional

This study will assess the safety and immunogenicity of ProQuad when administered concomitantly and nonconcomitantly with Tripedia and Comvax.

NCT ID: NCT00975507 Completed - Measles Clinical Trials

ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)

Start date: March 1998
Phase: Phase 3
Study type: Interventional

This study will compare Measles, Mumps, Rubella, and Varicella Vaccine (V221) and concomitant administration of Varivax and M-M-R II vaccines in healthy children.

NCT ID: NCT00969436 Completed - Measles Clinical Trials

Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM

Start date: November 9, 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess non-inferiority of two different vaccination regimens using GSK Biological's MMRV vaccine (two doses at 9 and 15 months) or Priorix™ (9 months) and one dose of MMRV vaccine (15 months) to the current standard of care which is Priorix™ administered at 9 months of age followed by concomitant administration of Priorix™ with Varilrix™ at 15 months of age in a measles endemic environment such as India.

NCT ID: NCT00892775 Completed - Measles Clinical Trials

Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds

Start date: June 3, 2009
Phase: Phase 2
Study type: Interventional

This study is undertaken to generate clinical data on GSK Biologicals' combined measles-mumps-rubella-varicella vaccine manufactured with measles and rubella obtained from newly established working seed viruses which are one passage further than the current working seed viruses. The measles-mumps-rubella-varicella vaccine manufactured with the current working seed viruses will serve as comparator. A seed lot system is a system according to which successive batches of a vaccine are derived from the same master seed virus. For routine production, a working seed lot is prepared from the master seed virus.

NCT ID: NCT00830648 Completed - Varicella Clinical Trials

Safety of a Second Dose of Biken's Varicella Vaccine

Start date: January 2009
Phase: Phase 4
Study type: Interventional

The objective of the present study is to assess and document the safety of a second dose of Varicella Biken vaccine administered at 4 to 6 years of age in healthy children having previously received a first dose of Varicella Biken vaccine. All subjects will receive a second dose of Varicella vaccine (Varicella Biken) at 4 to 6 years of age. The expected total duration of follow-up (first visit to last visit) for each subject will be one month.

NCT ID: NCT00822237 Completed - Varicella Clinical Trials

Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed)

Start date: January 2009
Phase: Phase 3
Study type: Interventional

This study will test the safety, tolerability, and immunogenicity of VARIVAX manufactured with the 2007 commercial Varicella-Zoster Virus (VZV) bulk process when concomitantly administered with M-M-R II in healthy children.

NCT ID: NCT00792623 Completed - Varicella Clinical Trials

Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM).

Start date: September 8, 2003
Phase: Phase 2
Study type: Interventional

This study aims to assess the immunogenicity and safety of varicella vaccination in a population of autologous peripheral stem cell/ bone marrow transplantation recipients who have reached at least four months post-transplantation.

NCT ID: NCT00751348 Completed - Measles Clinical Trials

Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136

Start date: October 1, 2008
Phase: Phase 3
Study type: Interventional

This Phase 3b study is being conducted for the purpose of registration of the GSK208136 vaccine in Korea.